Sort
8,912 grants matching “sars cov 2”
Project 3 Supplement - A Novel Cellular Tumor Vaccine Strategy for Mutant IDH1 glioma
$160,934John H Sampson · Duke University · P50 · FY2020 · CA
K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplant
$160,518Susan Conway · Children'S Research Institute · K23 · FY2024 · HL
K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplant
$160,518Susan Conway · Children'S Research Institute · K23 · FY2025 · HL
Core C - Modeling Core
$160,485Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · U19 · FY2024 · AI
Stigma, Risk Behaviors and Health Care among HIV-infected Russian People Who Inject Drugs
$160,369Karsten Lunze · Boston Medical Center · R00 · FY2020 · DA
Defining antiviral T cell responses restricted to the non-classical MHC class Ib molecule, Qa-1
$160,205Michael John Hogan · University Of Pennsylvania · K22 · FY2024 · AI
Design and validation of VLP/mRNA-based vaccine strategies against SARS-CoV2
$160,169Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Development of technologies for evaluation of antibody response following Coronavirus Infection vs Vaccination to identify immune correlates of protection
$160,000Hana Golding · National Institute Of Allergy And Infectious Diseases · Y01 · FY2020 · AI
USG Operation COVID-19 Therapeutics Research Team-FDA Evaluations of the Neutralization Potency of Therapeutic Antibodies against SARS-CoV-2 Variants
$160,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2022 · AI
The Jackson Laboratory Knockout Mouse Production and Phenotyping Project (JAX KOMP2)
$160,000Robert E Braun · Jackson Laboratory · UM1 · FY2021 · OD
EAGER: Rapid Identification of Anti-diabetic Agents Which Influence SARS-CoV-2 Entry in Adipocytes
$160,000Nikhil V Dhurandhar · Texas Tech University · · FY2020 · ENG
Defining cell-intrinsic utilization, cofactor balancing, and metabolomic signatures of NAD+ in pancreatic cancer
$160,000Sarah H. Elsea · Baylor College Of Medicine · R01 · FY2020 · CA
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
$159,890Avrum E Spira · Boston University Medical Campus · U2C · FY2020 · CA
Economic security and health disparity in COVID-19: A computational modeling approach.
$159,842James Moody · Duke University · R21 · FY2021 · HD
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$159,630Ignacio E. Sanz · Emory University · U54 · FY2022 · CA
The ADELANTE Trial: Testing a multi-level approach for improving household food insecurity and glycemic control among Latinos with diabetes
$159,542Lisa Goldman Rosas · Stanford University · R01 · FY2024 · MD
Identifying and Engaging Urban HIV infected and uninfected YSMSM in care
$159,411David D. Celentano · Johns Hopkins University · R01 · FY2020 · DA
Genes, substance use, and HIV outcomes in people living with HIV across the US
$159,270Heidi M. Crane · University Of Washington · R01 · FY2021 · DA
CEIRS - SARS-CoV-2 Research
$158,911Walter A. Orenstein · Emory University · N01 · FY2021 · AI
CRST COVID-19 - Wayakta He
$158,832Esther Erdei · University Of New Mexico Health Scis Ctr · R21 · FY2022 · ES
Clinical Core
$158,760Pandurangan Vijayanand · La Jolla Institute For Immunology · U19 · FY2022 · AI
Impact of Medical and Recreational Marijuana Laws on Cannabis, Opioids and Psychiatric Medications: National Study of VA Patients, 2000 -2024
$158,569Deborah S. Hasin · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · R01 · FY2020 · DA
Chemokine CXCL12/CXCR4 system and synthetic cathinones
$158,500Scott M Rawls · Temple Univ Of The Commonwealth · R01 · FY2020 · DA
Inhibition of coronavirus release and mitigate COVID-19 pathogenesis
$158,373Peter D. Sun · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
$158,208Ann M Moormann · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA